shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
15 April 2020Big PharmaRory O'Neill

Indian NGO wants Gilead patents cancelled

An association representing Indian cancer patients has asked the country’s government to cancel  Gilead Sciences’ patents on remdesivir, the experimental antiviral which is hoped can be used to treat coronavirus.

Remdesivir has emerged as one of the most promising candidates for a potential treatment for the coronavirus behind the current COVID-19 pandemic.

The drug is currently in clinical trials to test its efficacy and safety for treating COVID-19, having originally been developed as an investigational ebola drug.

Gilead, which originally developed the drug, is now facing pressure amid criticism over a potential monopoly.

Earlier this month, almost 150 health and poverty campaigns including  Médecins Sans Frontières urged Gilead to waive all patent rights for the drug.

Now, India’s  Cancer Patients Aid Association has asked the government to unilaterally revoke Gilead’s patents for the antiviral.

“It is imperative at a time like this that no monopoly rights be granted, so that more manufacturers can produce the drug to be made available to all the people who need it, at affordable costs,” said a letter from the CPAA to India’s minister of chemicals and pharmaceuticals.

The CPAA said cancer patients were at particular risk of severe illness from COVID-19, including those undergoing chemotherapy and/or radical radiotherapy, as well as those with lung, blood, and bone marrow cancers.

There is growing scrutiny on Gilead’s remdesivir patents, especially after a controversy over the company receiving the lucrative ‘ orphan drug’ designation for remdesivir from the US Food and Drug Administration (FDA).

This designation is reserved for drugs which treat rare diseases, and Gilead’s decision to claim it for remdesivir during the coronavirus pandemic drew criticism, including from US senator Bernie Sanders. Gilead subsequently asked the FDA to rescind the designation.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.


More on this story

Big Pharma
26 March 2020   Gilead Sciences has agreed to drop the lucrative “orphan drug” designation for an antiviral touted as a potential coronavirus treatment, after criticism from activists and politicians including Bernie Sanders.
Big Pharma
27 February 2020   US-based Gilead Sciences has been granted three Chinese patents connected to possible COVID-19 treatment remdesivir, reported He Zhimin, the deputy director of China’s National Intellectual Property Administration.
Generics
14 May 2020   Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.

More on this story

Big Pharma
26 March 2020   Gilead Sciences has agreed to drop the lucrative “orphan drug” designation for an antiviral touted as a potential coronavirus treatment, after criticism from activists and politicians including Bernie Sanders.
Big Pharma
27 February 2020   US-based Gilead Sciences has been granted three Chinese patents connected to possible COVID-19 treatment remdesivir, reported He Zhimin, the deputy director of China’s National Intellectual Property Administration.
Generics
14 May 2020   Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.